AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04527666
Drug: Anticoagulation Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.
Trial: NCT00864786
Drug: PF03635659
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled doses of 200 mcgQD
Trial: NCT00864786
Drug: PF03635659
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled doses of 600 mcg QD
Trial: NCT00864786
Drug: PF03635659
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
Trial: NCT00935662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, placebo
Trial: NCT01043263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily dosing
Trial: NCT01518478
Drug: Fluzone® Intradermal (Sanofi Pasteur Inc.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzone® Intradermal trivalent vaccine is a clear-to-slightly opalescent, preservative-free suspension containing formaldehyde-inactivated split influenza viruses for intradermal delivery of 0.1 mL via an ultra-fine micro-needle. The vaccine is supplied as a single-dose, in a latex-free, pre-filled microinjection system. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs.~Fluzone® Intradermal is standardized according to United States Public Health Service (US PHS) requirements and is formulated to contain HA of each of the following three influenza strains recommended for the 2011-2012 influenza season: A/California/07/2009 X-179A (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/60/2008-like virus.
Trial: NCT03441204
Drug: LTOT 24 h/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTOT prescribed for 24 h/day.
Trial: NCT03441204
Drug: LTOT 15h/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: : LTOT prescribed for 15 h/day. The patient is instructed to use LTOT during sleep and not to use LTOT for about 9 hours during daytime, totalling 15 h/day.
Trial: NCT02071329
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03783754
Drug: telmisartan 20 mg + amlodipine 2.5mg + indapamide 1.25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low-dose combination therapy
Trial: NCT03783754
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo
Trial: NCT01170468
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally, daily for 2 years
Trial: NCT04778917
Drug: Low-Molecular-Weight Heparins Calcium Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We use different dose of low-molecular-weight heparins calcium injection to different interventions
Trial: NCT01274026
Drug: sapropterin dihydrochloride
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In 30 PKU patients found previously to exhibit no decrease in blood PHE levels behavioral and cognitive function, neurotransmitter levels, and gene expression of enzyme activity will be measured at baseline and after 4 weeks of Kuvan administration. Rating inventories of executive function performance and behavior will be administered to patients and parents.~Urine neurotransmitters, blood microarray expression, and plasma amino acids will be measured (plasma PHE and TYR levels will also be measured at weeks 1 and 2). Nutrient analysis of 3 day food diaries will be conducted.
Trial: NCT04553978
Drug: WD-1603
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
Trial: NCT01667289
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy
Trial: NCT01174940
Drug: extracorporeal photopheresis
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 2 ECP treatments prior to the commencement of the high dose chemotherapy and then for two consecutive days every two weeks starting from post engraftment (ANC \> 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.~The dose of UVADEX® used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, using the following formula:~Treatment Volume in mL X 0.017 of UVADEX® (20 mcg/ml) required for administration into the recirculation bag = Amount of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX®, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then re-infused back into the patient.
Trial: NCT01356758
Drug: biological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients treated with anti-psoriatic biological agents
Trial: NCT03098810
Drug: Zinc sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral syrup zinc sulphate
Trial: NCT02279160
Drug: APD811
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02279160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04139655
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
Trial: NCT00634751
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each course of oral capecitabine administration will commence following administration of oxaliplatin. Capecitabine 2250 mg/m2 will be given every 8 hours for a total of 6 doses as above, commencing with each cycle of therapy. Because capecitabine is provided in fixed dose forms, rounding will be necessary. Rounding will be to the nearest 150 mg on a per dose basis.
Trial: NCT04402385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to placebo daily
Trial: NCT04469556
Drug: Folfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT01287988
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were exposed to a single intravitreal injection of placebo in a previous phase III study TG-MV-006 or TG-MV-007
Trial: NCT00442611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03286634
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO or IV
Trial: NCT03286634
Drug: E-coli L-asparaginase
RxNorm normalized name: E.COLI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IM or IV
Trial: NCT03286634
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV, PO or IT
Trial: NCT03286634
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IT
Trial: NCT03286634
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01511692
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide placebo, injected subcutaneously for 4 weeks
Trial: NCT01511692
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks
Trial: NCT04349072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02675907
Drug: Intravenous Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00655122
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered with a daily injection of 0.2 mL by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
Trial: NCT05326906
Drug: PD-1/PD-L1 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/PD-L1 inhibitors (the dosage calculation according to dosing instructions)
Trial: NCT00405275
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: baseline methotrexate is maintained throughout the study and is not provided by the sponsor
Trial: NCT00405275
Drug: Placebo, triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in Etanercept arm (Arm 1) were given placebo hydroxychloroquine and sulfasalazine pills.
Trial: NCT00608894
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
Trial: NCT03180294
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: By mouth
Trial: NCT03360903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthetized volunteers will be allowed to wake after injection of saline (placebo control).~Other Names:~* Saline
Trial: NCT00362869
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate solution
Trial: NCT02570711
Drug: ACP-196
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACP-196 capsule
Trial: NCT03360903
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg).~Other Names:~* Caffeine citrate
Trial: NCT02242695
Drug: Fluomizin vaginal tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One vaginal tablet for 6 days and 1 placebo tablet on day 7
Trial: NCT00162292
Drug: BMS-582949 and Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01422161
Drug: Botulinum Toxin commonly known as BOTOX®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total dose between 200-300 units of Botulinum toxin will be administered across 12 muscles of the affected hand.~There will be 1 treatment cycle during the 9 week study.
Trial: NCT01422161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will receive a placebo injection.
Trial: NCT00144144
Drug: Angiotensin II receptor antagonists, Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03093467
Drug: Antidepressants or in combination with anxiolytics, neuroleptics or mood stabilizers.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual psychiatric treatment which may include drugs: antidepressant monotherapy or antidepressants in combination with anxiolytics, neuroleptics or mood stabilizers as needed, according to the psychiatric evaluation. Monthly controls during 5 months in average.
Trial: NCT03622216
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for Bradanicline
Trial: NCT02415595
Drug: TDF/FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF/FTC
Trial: NCT01426724
Drug: Contrast Enhanced Ultrasonography
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Definity microbubbles will be infused intravenously at a rate of 2mL/min. contrast enhanced images of the kidneys will be obtained during the infusion and following the destruction of microbubbles within the kidney tissue with ultrasound to measure renal blood flow two times within a 90 day (plus or minus 10 day) window
Trial: NCT00036231
Drug: RG1068 (Synthetic Human Secretin)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03189537
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule to match Ingavirin capsule
Trial: NCT01480791
Drug: Aliskiren vs. hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren will be used at increasing doses from 150 to 300 mg per day for 6-12 months.
Trial: NCT02250391
Drug: NPB-06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days continuous-infusion
Trial: NCT02250391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days continuous-infusion
Trial: NCT04388683
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive iNO using the INO pulse device at a dose of 125 mcg/kg IBW/hr (equivalent to approximately 20 ppm). The clinical disease severity will be assessed pre-randomization as the worse of 2 scores measured 2 hours apart. Patients eligible for randomization will be those with scores of 1 or 2 (below), and randomization will be stratified according to score (1 or 2). Study drug will begin within 1 hour of randomization. Beginning on the day following randomization (day 1), we will be calculate clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6AM, 2PM, and 10PM.
Trial: NCT01700140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug patches (Placebo group: SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 placebo patch) assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
Trial: NCT01060124
Drug: Fentanyl D-trans
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl D-trans will be applied as transdermal patch releasing drug at the rate of 12.5 microgram per hour (mcg/hr) for 3 days with a dose ranging from 12 mcg/hr to 50 mcg/hr.
Trial: NCT02631980
Drug: IV iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron 15 mg/kg (max 1000 mg) in 250 ml 0.9% saline
Trial: NCT04218110
Drug: Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of antiseptic drug to the inguinal area of the subjects
Trial: NCT04218110
Drug: Prevantics 3.15 % / 70 % Swabstick
RxNorm normalized name: Prevantics 3.15 % / 70 % Swabstick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of antiseptic drug to the inguinal area of the subjects
Trial: NCT01908296
Drug: FK949E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02631980
Drug: IV placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.9% saline (250 ml)
Trial: NCT02598596
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (1.25 mg/kg, followed by 2.5 mg/kg) oral, daily
Trial: NCT02835235
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered daily subcutaneously (s.c., under the skin)
Trial: NCT04092686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet dosed once daily
Trial: NCT02264158
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00896350
Drug: Standard Care Chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam radiation to the neck and tumor site of head and neck. Concurrent platinum based chemotherapy. External beam boost at discretion of treating physician.
Trial: NCT00002842
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m2/day by intravenous bolus 24 hours apart for 5 consecutive days.
Trial: NCT00002842
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m2/day by continuous intravenous infusion beginning 24 hours prior to the first dose of 5-FU and continuing until 12 hours following the last dose of 5-FU.
Trial: NCT01228838
Drug: NGX-1998
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin topical liquid to be applied for 5 minutes one time only.
Trial: NCT01228838
Drug: Placebo Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo topical liquid to be applied for 5 minutes one time only.
Trial: NCT00333021
Drug: GSK576428
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03074409
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self-administration of placebo (nasal spray)
Trial: NCT05360927
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT01475877
Drug: Bromfenac
RxNorm normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromfenac 0.09% 1 drop in study eyes q day
Trial: NCT03449758
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:Tablet Route of administration: Oral
Trial: NCT03449758
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous / Intramuscular
Trial: NCT01759628
Drug: H.pylori eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
Trial: NCT02933788
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin may prevent coronary thrombosis in patients with cardiovascular event risk factors, such as ischemic heart disease family history, hypertension, diabetes mellitus, dyslipidemia and obesity.
Trial: NCT01868594
Drug: Subetta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type I diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Trial: NCT01868594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type I diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Trial: NCT00410514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00471692
Drug: Ropivicaine
RxNorm normalized name: Ropivicaine-Sufentanil Citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03306667
Drug: FYU-981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single dosing
Trial: NCT01815944
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01815944
Drug: Dextrose 5%
RxNorm normalized name: Dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01879917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT04381858
Drug: Plasma from COVID-19 convalescent patient
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 400 ml (2 units) of plasma.~Plasma donated from convalescent patients will be extracted in strict compliance with the following criteria:~* History of a clinical event with symptoms attributed to COVID-19 and a positive PCR test for COVID-19~* Further confirmation of a negative PCR test for COVID-19~* In order to be eligible plasma donors must complete at least 14 days after the last negative PCR in the absence of any symptom attributable to COVID-19 infection~* IgG antibodies for COVID-19 must be confirmed POSITIVE when a qualitative assay is being used~* When quantification of IgG antibodies for COVID-19 is available a title \> 1: 640 will be required for inclusion.~* Apheresis will be used as the only method for plasma extraction.
Trial: NCT02016976
Drug: EMLA Analgesic Cream
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02016976
Drug: Dormicum 2.5 mg and Pethidine 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine anesthesia and analgesia ( Dormicum 2.5 mg and Pethidine 25 mg )normally given to patients before and during pacemaker implantation
Trial: NCT03231722
Drug: l-leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/sqm iv over 2 hours
Trial: NCT00613782
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo injection 0,6.18.30 weeks